What is the net worth of Kymera?
Kymera Therapeutics has a market cap or net worth of $3. July 30, 2025. Its market cap has increased by 19. Kymera Therapeutics has 208 total employees.
Who owns Kymera?
Kymera has been owned by affiliates of palladium equity partners, llc (collectively, “palladium”), a middle market private equity firm with over $3 billion in assets under management, since 2018. Palladium equity partners acquires kymera international and 5n’s antimony powder assets. The single platform is rebranded to promote global products, established as kymera international.Kymera International’s top competitors include Keronite, Cirrus Materials Science, and 3M.
Is Kymera public?
Kymera Therapeutics has successfully priced a public offering of $250. The offering includes both common stock and pre-funded warrants, indicating strong investor interest and flexibility in financing options. NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.